PT Bundamedik Tbk (BMHS) Fair Value & Analysis
Healthcare · ID · Market cap 1.5T IDR
Fair value as of: Jul 16, 2026
From 23 valuation models · updated 25 days ago
Share price +9.1% over the past month.
Below-average quality, and screening another 83% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (39.70 IDR). The favourable scenario is already priced in.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range 146.15 IDR – 1,124 IDR · fair‑value band 23.82 IDR – 39.70 IDR · the 191.00 IDR price screens above the 31.76 IDR fair value. Dashed = 300-day average. As of Jul 16, 2026.
Analysis
PT Bundamedik Tbk (BMHS) currently trades at 191.00 IDR, while our model-based Fair Value estimate is 31.76 IDR, implying the stock looks roughly 83.4% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, PT Bundamedik Tbk generated revenue of 1.6T IDR at a net margin of 0.8%. Revenue grew 15.5% year over year. It earns a return on equity of 1.3%. Net debt stands at 529B IDR. Fundamentals as of Jul 16, 2026
Our scenario range runs from 23.82 IDR (bear case) to 39.70 IDR (bull case); at 191.00 IDR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 22% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -83%, BMHS screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 23 models by family
Widest divergence: Asset-Based (151.85 IDR) versus Earnings-Based (7.78 IDR). Highest evidence: Growth DCF (80).
Notify me when BMHS reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 47
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management …
Full company description
PT Bundamedik Tbk provides health care services in Indonesia. It also engages private hospital and healthcare support service activities; provision of ambulance services; private health education; consultant for reproductive technology services management; management consultant of physiotherapy service; and hotel, and dental clinic services management consulting businesses. It also provides fertility clinic, and oncology; emergency services; laboratory, radiology, and IVF services; and genomics and clinical pathology laboratory, and corporate health services. In addition, the company operates a BMHS nurse center, bunda neuro centre, bunda heart centre, bunda urology centre, digital substraction angiography, RSM oncology, and advanced robotic minimal invasive surgery. PT Bundamedik Tbk was founded in 1961 and is based in Jakarta Pusat, Indonesia. PT Bundamedik Tbk is a subsidiary of PT Bunda Investama Indonesia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Bundamedik Tbk reported revenue of 1.6T IDR in FY2025 versus 1.7T IDR in FY2021, a compound −1.4%/yr. Reported net income was 12.4B IDR in FY2025, compounding −55.5%/yr from FY2021.
BMHS screens 83% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare PT Bundamedik Tbk with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Bundamedik Tbk (BMHS) overvalued or undervalued?
What is the fair value of BMHS?
What is the quality score of BMHS?
What is the revenue of PT Bundamedik Tbk (BMHS)?
What is the net profit margin of BMHS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track PT Bundamedik Tbk and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.